AU1269092A - Monoclonal antibodies to elam-1 and their uses - Google Patents

Monoclonal antibodies to elam-1 and their uses

Info

Publication number: AU1269092A
Authority: AU; Australia
Prior art keywords: elam; immunoglobulin; cells; antibodies; antibody
Prior art date: 1991-01-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU12690/92A

Other languages

English (en)

Inventor

Mary L Phillips

Elisabeth Wayner

Jeffrey L. Winkelhake

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cytel Corp

Original Assignee

Cytel Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-24

Filing date

1992-01-23

Publication date

1992-08-27

1992-01-23 Application filed by Cytel Corp filed Critical Cytel Corp

1992-08-27 Publication of AU1269092A publication Critical patent/AU1269092A/en

Status Abandoned legal-status Critical Current

Links

102000015689 E-Selectin Human genes 0.000 title claims description 18
108010024212 E-Selectin Proteins 0.000 title claims description 18
238000000034 method Methods 0.000 claims description 62
108060003951 Immunoglobulin Proteins 0.000 claims description 44
102000018358 immunoglobulin Human genes 0.000 claims description 44
239000002502 liposome Substances 0.000 claims description 38
239000000203 mixture Substances 0.000 claims description 23
230000001404 mediated effect Effects 0.000 claims description 17
230000037396 body weight Effects 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
201000010099 disease Diseases 0.000 claims description 11
239000008194 pharmaceutical composition Substances 0.000 claims description 11
230000028709 inflammatory response Effects 0.000 claims description 9
230000005732 intercellular adhesion Effects 0.000 claims description 9
230000004044 response Effects 0.000 claims description 9
239000002246 antineoplastic agent Substances 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
206010040070 Septic Shock Diseases 0.000 claims description 5
229940127089 cytotoxic agent Drugs 0.000 claims description 5
230000036303 septic shock Effects 0.000 claims description 5
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
206010040047 Sepsis Diseases 0.000 claims description 4
208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 4
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
206010027476 Metastases Diseases 0.000 claims description 3
230000003110 anti-inflammatory effect Effects 0.000 claims description 3
230000009401 metastasis Effects 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims 2
210000004027 cell Anatomy 0.000 description 63
239000002158 endotoxin Substances 0.000 description 40
229920006008 lipopolysaccharide Polymers 0.000 description 34
238000003556 assay Methods 0.000 description 33
239000002609 medium Substances 0.000 description 25
210000003622 mature neutrocyte Anatomy 0.000 description 23
229940072221 immunoglobulins Drugs 0.000 description 22
210000002889 endothelial cell Anatomy 0.000 description 21
210000000440 neutrophil Anatomy 0.000 description 20
241000700159 Rattus Species 0.000 description 19
108090000184 Selectins Proteins 0.000 description 18
102000003800 Selectins Human genes 0.000 description 17
108090000623 proteins and genes Proteins 0.000 description 16
239000000725 suspension Substances 0.000 description 15
241001465754 Metazoa Species 0.000 description 14
210000004369 blood Anatomy 0.000 description 14
239000008280 blood Substances 0.000 description 14
102000005962 receptors Human genes 0.000 description 14
108020003175 receptors Proteins 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
239000003795 chemical substances by application Substances 0.000 description 12
239000011780 sodium chloride Substances 0.000 description 12
235000002639 sodium chloride Nutrition 0.000 description 12
229940079593 drug Drugs 0.000 description 11
239000003814 drug Substances 0.000 description 11
238000002347 injection Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 10
230000000694 effects Effects 0.000 description 10
239000000243 solution Substances 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
108091028043 Nucleic acid sequence Proteins 0.000 description 9
108010035766 P-Selectin Proteins 0.000 description 9
102000008212 P-Selectin Human genes 0.000 description 9
239000002253 acid Substances 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
239000012634 fragment Substances 0.000 description 9
230000008685 targeting Effects 0.000 description 9
238000011282 treatment Methods 0.000 description 9
210000003462 vein Anatomy 0.000 description 9
108091003079 Bovine Serum Albumin Proteins 0.000 description 8
230000000295 complement effect Effects 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
239000003446 ligand Substances 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
229940098773 bovine serum albumin Drugs 0.000 description 7
239000000872 buffer Substances 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
210000003038 endothelium Anatomy 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
210000000265 leukocyte Anatomy 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
PMTMAFAPLCGXGK-JMTMCXQRSA-N (15Z)-12-oxophyto-10,15-dienoic acid Chemical compound CC\C=C/C[C@H]1[C@@H](CCCCCCCC(O)=O)C=CC1=O PMTMAFAPLCGXGK-JMTMCXQRSA-N 0.000 description 6
OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 6
108020004414 DNA Proteins 0.000 description 6
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 6
108010010803 Gelatin Proteins 0.000 description 6
PMTMAFAPLCGXGK-UHFFFAOYSA-N OPDA Natural products CCC=CCC1C(CCCCCCCC(O)=O)C=CC1=O PMTMAFAPLCGXGK-UHFFFAOYSA-N 0.000 description 6
101100028078 Oryza sativa subsp. japonica OPR1 gene Proteins 0.000 description 6
208000027418 Wounds and injury Diseases 0.000 description 6
238000007792 addition Methods 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
239000000427 antigen Substances 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
239000008273 gelatin Substances 0.000 description 6
229920000159 gelatin Polymers 0.000 description 6
235000019322 gelatine Nutrition 0.000 description 6
235000011852 gelatine desserts Nutrition 0.000 description 6
208000027866 inflammatory disease Diseases 0.000 description 6
238000002156 mixing Methods 0.000 description 6
210000003281 pleural cavity Anatomy 0.000 description 6
239000011537 solubilization buffer Substances 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
239000007979 citrate buffer Substances 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
230000006870 function Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 5
238000012216 screening Methods 0.000 description 5
239000011550 stock solution Substances 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
102000000844 Cell Surface Receptors Human genes 0.000 description 4
108010001857 Cell Surface Receptors Proteins 0.000 description 4
239000007995 HEPES buffer Substances 0.000 description 4
239000012981 Hank's balanced salt solution Substances 0.000 description 4
108700005091 Immunoglobulin Genes Proteins 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
108010092694 L-Selectin Proteins 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
230000006378 damage Effects 0.000 description 4
239000003599 detergent Substances 0.000 description 4
239000012636 effector Substances 0.000 description 4
210000003989 endothelium vascular Anatomy 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
210000003714 granulocyte Anatomy 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
208000014674 injury Diseases 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000012071 phase Substances 0.000 description 4
208000008423 pleurisy Diseases 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
210000003556 vascular endothelial cell Anatomy 0.000 description 4
239000013598 vector Substances 0.000 description 4
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
102000029816 Collagenase Human genes 0.000 description 3
108060005980 Collagenase Proteins 0.000 description 3
238000012286 ELISA Assay Methods 0.000 description 3
101800003838 Epidermal growth factor Proteins 0.000 description 3
241000272184 Falconiformes Species 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
102000000589 Interleukin-1 Human genes 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
102000016551 L-selectin Human genes 0.000 description 3
102000012750 Membrane Glycoproteins Human genes 0.000 description 3
108010090054 Membrane Glycoproteins Proteins 0.000 description 3
241001529936 Murinae Species 0.000 description 3
102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
230000001464 adherent effect Effects 0.000 description 3
NIGUVXFURDGQKZ-UQTBNESHSA-N alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O NIGUVXFURDGQKZ-UQTBNESHSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000010367 cloning Methods 0.000 description 3
229960002424 collagenase Drugs 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
230000034994 death Effects 0.000 description 3
229940061607 dibasic sodium phosphate Drugs 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
238000009826 distribution Methods 0.000 description 3
230000003511 endothelial effect Effects 0.000 description 3
229940116977 epidermal growth factor Drugs 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000004968 inflammatory condition Effects 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
239000010410 layer Substances 0.000 description 3
231100000225 lethality Toxicity 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
239000002510 pyrogen Substances 0.000 description 3
230000010076 replication Effects 0.000 description 3
230000035886 specific defense system Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
102000005717 Myeloma Proteins Human genes 0.000 description 2
108010045503 Myeloma Proteins Proteins 0.000 description 2
108010003541 Platelet Activating Factor Proteins 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
230000004913 activation Effects 0.000 description 2
238000013019 agitation Methods 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
239000007975 buffered saline Substances 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
239000000539 dimer Substances 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
102000034356 gene-regulatory proteins Human genes 0.000 description 2
108091006104 gene-regulatory proteins Proteins 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
230000006698 induction Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000011694 lewis rat Methods 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
230000035781 nonspecific defense system Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000000527 sonication Methods 0.000 description 2
241000894007 species Species 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000009897 systematic effect Effects 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
238000005303 weighing Methods 0.000 description 2
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
201000001178 Bacterial Pneumonia Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
108090000342 C-Type Lectins Proteins 0.000 description 1
102000003930 C-Type Lectins Human genes 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000588921 Enterobacteriaceae Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
102000000646 Interleukin-3 Human genes 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000283953 Lagomorpha Species 0.000 description 1
239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
208000004852 Lung Injury Diseases 0.000 description 1
102000010836 Lymphocyte Homing Receptors Human genes 0.000 description 1
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010029719 Nonspecific reaction Diseases 0.000 description 1
102100023472 P-selectin Human genes 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
241000157426 Pernis Species 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
208000029464 Pulmonary infiltrates Diseases 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
241000607720 Serratia Species 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
208000033809 Suppuration Diseases 0.000 description 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
206010069363 Traumatic lung injury Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
239000003139 biocide Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
238000002059 diagnostic imaging Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
-1 etc. Substances 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
ZNOLGFHPUIJIMJ-UHFFFAOYSA-N fenitrothion Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C(C)=C1 ZNOLGFHPUIJIMJ-UHFFFAOYSA-N 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
210000000224 granular leucocyte Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000000703 high-speed centrifugation Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000006054 immunological memory Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000037456 inflammatory mechanism Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000013546 insoluble monolayer Substances 0.000 description 1
230000008611 intercellular interaction Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000005304 joining Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000503 lectinlike effect Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
231100000515 lung injury Toxicity 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000000693 micelle Substances 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
150000007523 nucleic acids Chemical group 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
238000007747 plating Methods 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000004739 secretory vesicle Anatomy 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229960001967 tacrolimus Drugs 0.000 description 1
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
210000004269 weibel-palade body Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Cell Biology (AREA)
Pain & Pain Management (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AU12690/92A 1991-01-24 1992-01-23 Monoclonal antibodies to elam-1 and their uses Abandoned AU1269092A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US64587891A	1991-01-24	1991-01-24
US645878		1991-01-24
US73303391A	1991-07-22	1991-07-22
US733033		1991-07-22

Publications (1)

Publication Number	Publication Date
AU1269092A true AU1269092A (en)	1992-08-27

Family

ID=27094802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU12690/92A Abandoned AU1269092A (en)	1991-01-24	1992-01-23	Monoclonal antibodies to elam-1 and their uses

Country Status (11)

Country	Link
EP (1)	EP0568631A4 (sk)
JP (1)	JPH06505253A (sk)
AU (1)	AU1269092A (sk)
CA (1)	CA2100681A1 (sk)
IE (1)	IE920206A1 (sk)
IL (1)	IL100764A0 (sk)
NO (1)	NO932672L (sk)
NZ (1)	NZ241399A (sk)
OA (1)	OA09809A (sk)
SK (1)	SK77393A3 (sk)
WO (1)	WO1992012729A1 (sk)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5646123A (en) *	1991-06-10	1997-07-08	Alberta Research Council	Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US5877289A (en) *	1992-03-05	1999-03-02	The Scripps Research Institute	Tissue factor compositions and ligands for the specific coagulation of vasculature
US5660827A (en) *	1992-03-05	1997-08-26	Board Of Regents, The University Of Texas System	Antibodies that bind to endoglin
US6749853B1 (en)	1992-03-05	2004-06-15	Board Of Regents, The University Of Texas System	Combined methods and compositions for coagulation and tumor treatment
US6004555A (en) *	1992-03-05	1999-12-21	Board Of Regents, The University Of Texas System	Methods for the specific coagulation of vasculature
US6036955A (en) *	1992-03-05	2000-03-14	The Scripps Research Institute	Kits and methods for the specific coagulation of vasculature
US5965132A (en)	1992-03-05	1999-10-12	Board Of Regents, The University Of Texas System	Methods and compositions for targeting the vasculature of solid tumors
US6093399A (en) *	1992-03-05	2000-07-25	Board Of Regents, The University Of Texas System	Methods and compositions for the specific coagulation of vasculature
ATE239506T1 (de) *	1992-03-05	2003-05-15	Univ Texas	Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US5643873A (en) *	1992-05-06	1997-07-01	Affymax Technologies N.V.	Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) *	1992-05-06	1997-07-15	Affymax Technologies N.V.	Peptides and compounds that bind to ELAM-1
US5728802A (en) *	1992-05-06	1998-03-17	Affymax Technologies N.V.	Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
EP0602290B1 (en) *	1992-12-04	1999-08-25	ConjuChem, Inc.	Antibody-conjugated Hepatitis B surface antigen and use thereof
US5723116A (en) *	1995-01-06	1998-03-03	University Of South Florida	Decreased mortality of severe acute pancreatitis following proximal cytokine blockade
WO1996040942A1 (en) *	1995-06-07	1996-12-19	Cytel Corporation	Humanized antibodies to e-selectin
US6537520B1 (en)	1998-03-31	2003-03-25	Bristol-Myers Squibb Pharma Company	Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en)	1998-03-31	2003-02-25	Bristol-Myers Squibb Pharma Company	Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en)	1998-03-31	2003-04-15	Bristol-Myers Squibb Pharma Company	Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6818213B1 (en)	1998-07-13	2004-11-16	Board Of Regents, The University Of Texas System	Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US7067109B1 (en)	1998-07-13	2006-06-27	Board Of Regents, The University Of Texas System	Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
US6794518B1 (en)	1998-12-18	2004-09-21	Bristol-Myers Squibb Pharma Company	Vitronectin receptor antagonist pharmaceuticals
TR200101757T2 (tr)	1998-12-18	2001-12-21	Dupont Pharmaceuticais Company	Vitronektin reseptör antagonisti farmasötikler
US6511649B1 (en)	1998-12-18	2003-01-28	Thomas D. Harris	Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en)	1998-12-18	2003-05-27	Bristol-Myers Squibb Pharma Company	Vitronectin receptor antagonist pharmaceuticals
CN1356913A (zh)	1998-12-18	2002-07-03	杜邦药品公司	玻连蛋白受体拮抗剂药物
US7030219B2 (en)	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
KR20110074850A (ko) *	2008-08-25	2011-07-04	앰플리뮨, 인크.	Ｐｄ-１ 길항제 및 그의 사용 방법
JP7185884B2 (ja)	2017-05-02	2022-12-08	国立研究開発法人国立精神・神経医療研究センター	Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2019078344A1 (ja) *	2017-10-20	2019-04-25	学校法人兵庫医科大学	抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
WO2021148983A1 (en)	2020-01-24	2021-07-29	Pfizer Inc.	Anti-e-selectin antibodies, compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04501565A (ja) *	1988-11-14	1992-03-19	ブリガム・アンド・ウイメンズ・ホスピタル	Ｅｌａｍ―１に特異的な抗体およびその用途
US5081034A (en) *	1988-11-14	1992-01-14	Brigham & Women's Hospital	Cloned genes which encode elam-1
US5272263A (en) *	1989-04-28	1993-12-21	Biogen, Inc.	DNA sequences encoding vascular cell adhesion molecules (VCAMS)

1992
- 1992-01-23 AU AU12690/92A patent/AU1269092A/en not_active Abandoned
- 1992-01-23 SK SK773-93A patent/SK77393A3/sk unknown
- 1992-01-23 IE IE020692A patent/IE920206A1/en not_active Application Discontinuation
- 1992-01-23 CA CA002100681A patent/CA2100681A1/en not_active Abandoned
- 1992-01-23 WO PCT/US1992/000577 patent/WO1992012729A1/en not_active Application Discontinuation
- 1992-01-23 EP EP92905123A patent/EP0568631A4/en not_active Withdrawn
- 1992-01-23 JP JP4505427A patent/JPH06505253A/ja active Pending
- 1992-01-24 IL IL100764A patent/IL100764A0/xx unknown
- 1992-01-24 NZ NZ241399A patent/NZ241399A/en unknown
1993
- 1993-07-22 OA OA60394A patent/OA09809A/en unknown
- 1993-07-23 NO NO93932672A patent/NO932672L/no unknown

Also Published As

Publication number	Publication date
NZ241399A (en)	1994-06-27
OA09809A (en)	1994-04-15
WO1992012729A1 (en)	1992-08-06
IL100764A0 (en)	1992-09-06
CA2100681A1 (en)	1992-07-25
IE920206A1 (en)	1992-07-29
NO932672D0 (no)	1993-07-23
EP0568631A1 (en)	1993-11-10
JPH06505253A (ja)	1994-06-16
EP0568631A4 (en)	1995-04-05
NO932672L (no)	1993-09-23
SK77393A3 (en)	1994-12-07

Publication	Publication Date	Title
AU1269092A (en)	1992-08-27	Monoclonal antibodies to elam-1 and their uses
Puri et al.	1995	Sialomucin CD34 is the major L-selectin ligand in human tonsil high endothelial venules.
JP3691467B2 (ja)	2005-09-07	セレクチンリガンド
US5417972A (en)	1995-05-23	Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US6210671B1 (en)	2001-04-03	Humanized antibodies reactive with L-selectin
AU689090B2 (en)	1998-03-26	Humanized antibodies reactive with L-selectin
AU674302B2 (en)	1996-12-19	Treatment for inflammatory bowel disease
EP0580763B1 (en)	2006-09-06	Compositions and methods for endothelial binding
EP1232184B1 (en)	2008-11-12	Antibody against the human toll-like receptor-2 (tlr2) and uses thereof
US5756095A (en)	1998-05-26	Antibodies with specificity for a common epitope on E-selectin and L-selectin
US5932217A (en)	1999-08-03	Peptides which inhibit adhesion between leukocytes and endothelial cells
US5580780A (en)	1996-12-03	Vascular adhesion protein-(VAP-1) and VAP-1-specific antibodies
EP0303463B1 (en)	1994-11-30	Method to control leukocyte extravasation
US5792457A (en)	1998-08-11	Antibody recognizing endothelial cell ligand for leukocyte CR3
CA2182215A1 (en)	1995-08-03	Anti-inflammatory containing monoclonal antibodies having reactivity with sialyl-lewis x sugar chains originating in hemangioendothelial cell membrane
EP0584273B1 (en)	1998-12-30	Antibody recognizing endothelial cell ligand for leukocyte cr3
EP0675735A1 (en)	1995-10-11	Method for modulating transendothelial migration of cells promoting inflammation, and related methods of measurement thereof
US7037496B2 (en)	2006-05-02	Chimeric immunoglobulin for CD4 receptors
WO1993002698A1 (en)	1993-02-18	Monoclonal antibodies to leukocyte adhesion molecule-1